Refine by
Diabetes Care Articles & Analysis
40 news found
Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
The diabetes vaccine Diamyd is uniquely well positioned to be studied for the prevention of clinical type 1 diabetes considering its strong safety profile and clinical efficacy in recent-onset type 1 diabetes”. ...
“These results are very important, as they show clinically meaningful effects of intralymphatic Diamyd on CGM outcomes that are of great importance to patients as they reflect the day-to-day challenges of managing their diabetes despite current best standard of care,” says Johnny Ludvigsson, Professor at Linköping University, Coordinating ...
Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the Omnipod Diabetes Management System, the ...
Longenesis announced today the preliminary results from its study on Type 1 Diabetes care in partnership with Medtronic. In less than three months, more than 85 patients participated in the research study, providing qualitative and quantitative data on the quality of life for Type 1 diabetics using insulin pumps compared to daily insulin ...
Our mission is to improve access to the highest standards of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." ...
(Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood glucose levels and avoid serious complications, such as loss of ...
China has the world’s largest Diabetic and resultingly Diabetic Foot Ulcer (DFU) population. The International Diabetes Federation estimates that 10.6% of the Chinese adult population now have diabetes that equates to 141 million people. ...
These open wounds may be vulnerable to infection. Proper diabetes wound care could help ward off a diabetes wound infection. Patients who take corticosteroids. ...
Ascensia Diabetes Care, a global diabetes company, announces that its partner Senseonics has received approval from the U.S. ...
The Eversense E3, including proprietary sacrificial boronic acid (SBA) technology to extend longevity to 6 months, is planned to be available to patients in the U.S. through Ascensia Diabetes Care, Senseonics’ global commercial partner, beginning in the second quarter of 2022. ...
Modular Medical, Inc., (NASDAQ:MODD) (the "Company" or "Modular Medical"), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, announced today the pricing of its underwritten public ...
REDWOOD CITY, Calif., Jan. 25, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today responded to Medtronic's announcement of FDA approval for painful diabetic neuropathy (PDN). "PDN represents a very large potential market, and having another competitor validate this large ...
” The research found that diabetic foot ulcer episodes-of-care were broadly associated with inpatient admissions for conditions not commonly thought to be associated with diabetic foot complications. ...
(NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational and financial business updates. ...
During his career, he has brought multiple systems and devices to market, including multiple blood glucose meters that have improved the lives of people with diabetes. Angus spent the first half of his career working in the defence and space industries but then transitioned into a career in medical devices, primarily within diabetes care and ...
Beyzavi is a seasoned veteran of the healthcare industry with significant operating experience in the medical device and diagnostics industries, and a focus on leveraging innovative technologies to improve diagnosis and delivery of care. Since starting her career at McKinsey & Company, she has over 25 years of experience as a venture investor, entrepreneur, consultant, and ...
(the "Company" or "Modular Medical") (OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, today announced the expansion of its Board of Directors with the appointment of ...